Oramed Pharmaceuticals (NASDAQ:ORMP) Downgraded by StockNews.com to “Sell”

Oramed Pharmaceuticals (NASDAQ:ORMP) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a report issued on Monday.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Oramed Pharmaceuticals in a report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 4.0 %

NASDAQ:ORMP traded up $0.09 during mid-day trading on Monday, reaching $2.47. 362,586 shares of the stock were exchanged, compared to its average volume of 132,574. The business has a fifty day moving average price of $2.36 and a 200 day moving average price of $2.38. Oramed Pharmaceuticals has a 1-year low of $2.00 and a 1-year high of $3.67. The firm has a market capitalization of $99.36 million, a PE ratio of 22.41 and a beta of 1.77.

Institutional Investors Weigh In On Oramed Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. XTX Topco Ltd acquired a new stake in Oramed Pharmaceuticals during the 2nd quarter worth about $40,000. Virtu Financial LLC acquired a new position in Oramed Pharmaceuticals in the 1st quarter worth approximately $68,000. Dimensional Fund Advisors LP grew its position in Oramed Pharmaceuticals by 52.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company’s stock worth $81,000 after purchasing an additional 10,774 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Oramed Pharmaceuticals during the 3rd quarter valued at $272,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Oramed Pharmaceuticals by 89.0% in the second quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company’s stock valued at $593,000 after purchasing an additional 108,700 shares in the last quarter. 12.73% of the stock is owned by hedge funds and other institutional investors.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.